ArticleEuropean journal of cancer (Oxford, England : 1990)2020
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors.
Article in European journal of cancer (Oxford, England : 1990), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.Technology in cancer research & treatmentTrial
- Cancer management during the COVID-19 world pandemic.Cancer immunology, immunotherapy : CII · 2023Review
- Serine-arginine protein kinases and their targets in viral infection and their inhibition.Cellular and molecular life sciences : CMLS · 2023Review
- COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore.Hereditary cancer in clinical practice · 2023Article
- Review
- Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication.Science signaling · 2022Article
- Article
- COVID-19, Mucormycosis and Cancer: The Triple Threat-Hypothesis or Reality?Journal of personalized medicine · 2022Review
- Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals.Frontiers in pharmacology · 2021Article
- Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues.Translational lung cancer research · 2021Review
- Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).European journal of cancer (Oxford, England : 1990) · 2020Article
- Commentary: Thoracic surgery during the COVID-19 pandemic: Recommendations from China.The Journal of thoracic and cardiovascular surgery · 2020Article
- Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.European journal of cancer (Oxford, England : 1990) · 2020Article
Corrections and comments
- Comment on
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.